Astria Therapeutics, Inc. (NASDAQ:ATXS) Receives $25.20 Average PT from Analysts

Shares of Astria Therapeutics, Inc. (NASDAQ:ATXS) have been assigned a consensus rating of “Buy” from the six brokerages that are covering the stock, Marketbeat Ratings reports. Five research analysts have rated the stock with a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year price objective among brokers that have covered the stock in the last year is $25.20.

A number of research analysts have commented on ATXS shares. HC Wainwright reaffirmed a “buy” rating and issued a $16.00 price objective on shares of Astria Therapeutics in a report on Friday, September 27th. TD Cowen started coverage on shares of Astria Therapeutics in a research note on Monday, July 29th. They issued a “buy” rating and a $35.00 price objective for the company. Oppenheimer boosted their price objective on shares of Astria Therapeutics from $25.00 to $26.00 and gave the company an “outperform” rating in a report on Tuesday, August 13th. Evercore ISI upgraded shares of Astria Therapeutics to a “strong-buy” rating in a research report on Wednesday, August 14th. Finally, Wedbush reissued an “outperform” rating and set a $22.00 price target on shares of Astria Therapeutics in a research report on Tuesday, August 13th.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. Quest Partners LLC increased its holdings in Astria Therapeutics by 3,310.6% in the second quarter. Quest Partners LLC now owns 3,206 shares of the biotechnology company’s stock valued at $29,000 after purchasing an additional 3,112 shares during the period. Ameritas Investment Partners Inc. increased its stake in shares of Astria Therapeutics by 135.6% in the first quarter. Ameritas Investment Partners Inc. now owns 4,971 shares of the biotechnology company’s stock valued at $70,000 after buying an additional 2,861 shares during the period. SG Americas Securities LLC acquired a new stake in shares of Astria Therapeutics in the third quarter valued at about $155,000. Price T Rowe Associates Inc. MD bought a new stake in Astria Therapeutics in the first quarter valued at approximately $200,000. Finally, Hsbc Holdings PLC acquired a new stake in Astria Therapeutics during the 2nd quarter valued at approximately $171,000. Institutional investors own 98.98% of the company’s stock.

Astria Therapeutics Stock Performance

Shares of NASDAQ ATXS opened at $11.32 on Wednesday. The stock has a 50 day moving average price of $11.54 and a 200 day moving average price of $10.51. The stock has a market capitalization of $638.73 million, a PE ratio of -4.92 and a beta of 0.71. Astria Therapeutics has a 52 week low of $4.26 and a 52 week high of $16.90.

Astria Therapeutics (NASDAQ:ATXS) last released its quarterly earnings data on Monday, August 12th. The biotechnology company reported ($0.43) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.05). As a group, research analysts forecast that Astria Therapeutics will post -1.68 EPS for the current year.

About Astria Therapeutics

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.